Terapia prechirurgica della fibromatosi uterina - FedOA - Università ...

10) Dubuisson JB, Fauconnier A, Fourchotte V, Babaki-Fard K, Coste J, Chapron C. Laparoscopic
myomectomy: predicting the risk of conversion to an open procedure. Hum Reprod 2001;
16(8): 1726-31.
11) Beyth Y. Gonadotropin-releasing hormone analog treatment should not precede conservative
myomectomy [letter]. Fertil Steril 1990; 53: 187-8.
12) Acien P, Quereda F. Abdominal myomectomy: results of a simple operative technique. Fertil
Steril 1996; 65: 41-51.
13) Sreenan, JJ, Prayson RA, Biscotti CV, Thornton MH, Easley KA, Hart WR. Histopathologic
findings in 107 uterine leiomyomas treated with leuprolide acetate compared with 126 controls.
Am J Surg Pathol 1996; 20(4): 427-32.
14) Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell proliferation and induction
of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide
acetate). J Clin Endocrinol Metab 1998; 84(4): 1253-5.
15) Vu K, Greenspan DL, Wu TC, Zacur HA, Kurman RJ. Cellular proliferation, estrogen receptor,
progesterone receptor, and Bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum
Pathol 1998; 29: 359-63.
16) Huang SC, Chou CY, Lin YS, et al. Enhanced deoxyribonucleic acid damage and repair but
unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone
agonist. Am J Obstet Gynecol 1997; 177(2): 417-24.
106